# S.D. Sight Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/s-d-sight-diagnostics

- Industry: Medical Devices & Equipment
- Headquarters: Tel Aviv, Israel
- Website: www.sightdx.com
- Total disclosed funding: $130M
- Latest round: Series D (Jul 23, 2020)
- Investors on record: 7

## About

S.D. Sight Diagnostics Ltd. specializes in advanced AI-driven diagnostic solutions, providing healthcare professionals with tools to enhance the speed and accuracy of blood analysis for better clinical decision-making.Founded in 2011 in Tel Aviv, Israel, S.D. Sight Diagnostics Ltd. focuses on developing innovative diagnostic systems for healthcare. The company was co-founded by Daniel Levner and Yossi Pollak, who previously founded other ventures. Notably, Sight Diagnostics has raised a total of USD 71.00 mn in funding, with its latest deal being a Series D round completed on July 23, 2020, co-led by Clal Biotechnology and Koch Disruptive Technologies, among others.Sight Diagnostics provides advanced diagnostic solutions that leverage artificial intelligence and proprietary data analytics to analyze live cells. Their flagship products are aimed at improving blood analysis speed and accuracy, addressing medical needs such as infectious disease detection and blood health monitoring. The company serves a wide client base, including hospitals and diagnostic laboratories across North America, Europe, and select Asian markets, contributing to more reliable diagnostic workflows.Sight Diagnostics generates revenue through direct sales of its diagnostic systems to healthcare providers and institutions. This model includes potential partnerships that may involve subscription services for software and ongoing support, along with sales contracts for equipment and maintenance, allowing for ongoing client relationships and updates to diagnostic technology.Following its Series D funding of USD 71.00 mn in July 2020, S.D. Sight Diagnostics Ltd. plans to utilize this investment to expand its presence in the U.S. market. The company aims to support users in adopting AI-driven diagnostics for a range of health conditions, positioning itself for future advancements in diagnostic solutions.

## Funding rounds

- Series D, Jul 23, 2020, $71M — Go Capital, Clal Biotechnology, New Alliance Capital, OurCrowd, Koch Disruptive Technologies, Longliv Ventures
- Series C, Feb 14, 2019, $28M — Go Capital, New Alliance Capital, Longliv Ventures
- Series B, Sep 1, 2016, $16M — New Alliance Capital, OurCrowd, Go Capital
- Series A, Nov 1, 2014, $6M — Clal Biotechnology, OurCrowd, Emery Capital
- Series A, Nov 1, 2014, $6M — New Alliance Capital, OurCrowd, Go Capital
- Seed, Aug 1, 2011, $3M — OurCrowd

## Investors

- OurCrowd (https://capitalatlas.ai/funds/ourcrowd) — Seed, Series A, Series B, Series D
- Clal Biotechnology (https://capitalatlas.ai/funds/clal-biotechnology) — Series A, Series D
- Emery Capital — Series A
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series A, Series B, Series C, Series D
- Go Capital — Series A, Series B, Series C, Series D
- Longliv Ventures — Series C, Series D
- Koch Disruptive Technologies (https://capitalatlas.ai/funds/koch-disruptive-technologies) — Series D